More R&D: Not Boosting Big Pharma
Drug industry R&D spending, by U.S. members of PhRMA, an industry trade group, expanded 20% from 2004 through 2007. Yet the number of Food & Drug Administration-approved new molecular entities and novel biologics declined from 36 to 18 over the same period. This attrition occurred despite important advances in R&D technology platforms, such as rational drug design and genomics earlier in the decade.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.